Navigation Links
Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy
Date:8/1/2009

SAN FRANCISCO (August 1, 2009)Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.

Both cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth factor receptor (EGFR) and the assumption has been that once a patient progresses on one EGFR inhibitor they will not respond to another EGFR inhibitor. The new data suggests that may not be the case.

"Just because a patient received and progressed on one EGFR inhibitor doesn't necessarily mean they will not derive clinical benefit from another one," says Hossein Borghaei, D.O., medical oncologist at Fox Chase. "And for patients who don't have a lot of treatment options, we think this is a good thing. It gives them one more drug to try when their disease is progressing."

To find out if patients whose disease is no longer controlled by cetuximab can respond to erlotinib, Borghaei and colleagues examined the treatment and clinical outcomes for a subgroup of patients who had participated in a Fox Chase clinical trial that tested a combination of carboplatin, paclitaxel and cetuximab as first-line treatment for advanced non-small cell lung cancer. Out of 53 patients who had participated in that trial, the investigators identified 15 individuals who had received erlotinib during subsequent therapy.

Of those 15 patients who received erlotinib, three remain on erlotinib. For the 12 patients who are no longer on erlotinib, the median duration of erlotinib therapy was 63 days, with a range from 36 to 222 days. The three patients remaining on therapy have been on the drug for 41, 238, and 459 days. The median progression-free survival time on erlotinib was 2.5 months for all 15 patients.

"It appears that some patients can enjoy durable disease control on erlotinib after progressing on cetuximab," Borghaei says. He cautions, however, that these data come from a subset analysis and are retrospective, so they are not conclusive, but are only hypothesis generating.

Although erlotinib is approved for use in patients with non-small cell lung cancer and cetuximab has been studied in this setting for several years, this is the first formal analysis to show that the drugs can be used in sequence. The tumor characteristics that predict clinical benefit from erlotinib after progression on a cetuximab-containing regimen is yet to be elucidated, but that is an area Dr. Borghaei would like to address in future studies.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
2. Northstar Healthcare Announces Option to Purchase a 60% Interest in The Palladium for Surgery - Dallas
3. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
4. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
5. Kensey Nash Announces $25 Million Stock Repurchase Program
6. Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance
7. Flextronics Announces Redemption and Change of Control Repurchase Offer for Solectron 8.00% Senior Subordinated Notes and Planned Change of Control Repurchase Offer for Solectrons 0.50% Senior Convertible Notes
8. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
9. Hospital Corporation of America Purchases Seventh CyberKnife(R) System
10. Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics
11. Governor Schwarzeneggers Mandatory Purchase of Private Health Insurance Doesnt Add Up for the Middle-Class, Says FTCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 31, 2016 , ... Twenty years ago it was revolutionary: enabling the people ... the voices they hear. But this approach has proven transformative, both for people who ... gained credibility and now is used around the world, but it still lags in ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... commercial molecular diagnostics device that enables unprecedented portability and convenience. , The Cube ... four inches cubed in size, the Cube fits easily into any space, whether ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... WaterField Designs, ... digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ideal ... canvas or ballistic nylon, the Duo is smartly designed for Dad’s grooming ...
(Date:5/31/2016)... ... May 31, 2016 , ... Phynd Technologies, Inc. announced recently the signing of ... TX and Shore Medical Center – Somers Point, NJ. The new clients range in ... demonstrating the breadth of Phynd’s solution and its interoperability. , Houston Methodist is a ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... firm and statement solutions provider, for the tenth consecutive year as a ... issue of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... Mich. , May 31, 2016  Diplomat Pharmacy, Inc. ... pharmacy, has announced that Phil Hagerman , Chairman & ... the upcoming William Blair 36 th Annual Growth Stock ... Mr. Hagerman and Mr. Whelan are scheduled to present at ... Central Time. A live audio-only webcast of the presentation and ...
(Date:5/31/2016)... , May 31, 2016 Mundipharma ... initiation of a first-in-human clinical trial of its investigational ... - S101 is currently being developed for the treatment ... is designed to evaluate the safety and tolerability of ... several sites across the United States ...
(Date:5/31/2016)... The global biomaterials market is driven by the ... from chronic diseases. According to research report, "Global Biomaterials Market ... Forecasts (2016-2021) - (By Value; By Material Type - Polymer, ... By Region-North America, Europe , APAC, ROW; ... Italy , Japan , ...
Breaking Medicine Technology: